| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3114 | lm-24 Hydrochloride | Novel p75NTR antagonist |
|
| DCC3115 | lmc-21 | Novel AI-2 quorum-sensing inhibitor, affecting the starvation response and reducing virulence in several Vibrio species, most likely by interfering with LuxPQ |
|
| DCC3116 | Lmptp-in-5d | Novel highly selective inhibitor of the low-molecular-weight protein tyrosine phosphatase (LMPTP), being highly orally bioavailable and reversing obesity-induced diabetes in mice |
|
| DCC3117 | Ln3844 | Novel Two-in-One Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites |
|
| DCC3118 | lnp-509 | Potent and selective ligand of imidazoline 1 receptor (I 1 R) |
|
| DCC3119 | Lnp599 Hydrochloride | Novel potent and specific agonist of I 1 imidazoline receptors |
|
| DCC3120 | Lobeglitazone Sulfate Featured | Peroxisome proliferator-activated receptor-α/γ (PPAR α/γ) dual agonist |
|
| DCC3121 | Lobelane Hydrochloride | Inhibitor of the Vesicular_monoamine_transporter_2>vesicular monoamine transporter-2 (VMAT2) |
|
| DCC3122 | Lomefloxacin | Antibiotic for treatment of bacterial infections including bronchitis and urinary tract infections, prevent urinary tract infections prior to surgery |
|
| DCC3123 | Longanlactone | Natural neurotrophic agent |
|
| DCC3124 | Loperamide | Opioid receptor agonist, acting on the µ-opioid receptors in the myenteric plexus of the large intestine |
|
| DCC3125 | Lopinavir M-3/m-4 | Lopinavir Secondary Metabolite |
|
| DCC3126 | Lox-activity Sensor-1 | Novel LOX-activity sensor for cross-linking with a collagen peptide to chemoselectively target endogenous aldehydes generated by LOX |
|
| DCC3127 | Lp-20 Hydrochloride | Potent ligand of the 5-HT7 receptor |
|
| DCC3128 | Lp-261 | Potent antimitotic and oral tubulin binding agent, significantly inhibiting growth of a human non-small-cell lung tumor |
|
| DCC3129 | Lp-922761 | Novel potent and selective peripheral AAK1 inhibitor |
|
| DCC3130 | Lp-925219 | Novel inhibitor of both renal SGLT1 and SGLT2 |
|
| DCC3131 | Lpa1-3 Agonist Cpx | Novel LPA 1-3 agonist, inducing a calcium response in hLPA 1-3 cells within a range of 0.4 to 1.5-log lower potency, as compared to LPA |
|
| DCC3132 | Lpa1-3 Agonist Cpy | Novel LPA 1-3 agonist, inducing a calcium response in hLPA 1-3 cells within a range of 0.4 to 1.5-log lower potency, as compared to LPA |
|
| DCC3133 | Lqfm030 | Novel p53 activator through the inhibition of MDM2 |
|
| DCC3134 | Lqmed 330 | Novel potent and specific inhibitor of O-linked β-N-acetylglucosamine transferase (OGT) |
|
| DCC3135 | Lrh-1 Agonist 10ca | Novel agonist of liver receptor homolog-1 (LRH-1), reducing the expression of lipogenic genes in mouse liver, and inflammation and disease severity in a mouse model of ulcerative colitis |
|
| DCC3136 | Lrh-1 Agonist-6n | Novel potent agonist of the liver receptor homolog-1 (LRH-1, NR5A2) |
|
| DCC3137 | Lrh-1 Inhibitor-3 | The first small molecule antagonist of LRH-1 activity. |
|
| DCC3138 | Lsd1 Inhibitor L8 | Novel selective and reversible LSD1 inhibitor (IC50 value of 60 nM), exhibiting the antiproliferative activity against HTB5, HTB3, HT1376, and HTB1 cells with IC50 values of 1.87, 0.18, 0.09, and 0.93 μM, respectively |
|
| DCC3139 | Lsd1-in-c26 | Novel selective inhibitor of histone lysine specific demethylase 1 (LSD1/KDM1A), displaying FAD-competitive binding to LSD1, concentration-dependently inducing accumulation of H3K4me1/me2 and H3K9me2, increasing expression levels of epithelial cell marker |
|
| DCC3140 | Lsf-oa | Novel prodrug of Lisofylline, maintaining a steady fasting blood glucose level with a significant increase in insulin level |
|
| DCC3141 | Lsf-pa | Novel prodrug of Lisofylline, maintaining a steady fasting blood glucose level with a significant increase in insulin level |
|
| DCC3142 | Lsm-4144 | First-in-class inhibitor of NF-κB signaling pathway by preventing the maturation of a rate-limiting multiprotein complex necessary for IKK activation |
|
| DCC3143 | Lsn3160440 | Novel positive allosteric modulator (PAM) of the GLP-1R, enhancing insulin secretion in a glucose-, ligand- and GLP-1R-dependent manner |
|
